In terms of systemic manifestations at PAD evaluation, patients with abnormal SPP exhibited cutaneous manifestation more frequently than those with normal SPP (83.3% vs. 5.9%, p = 0.001). The gene discussed is HM13; the disease is peripheral arterial disease.